Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

DISEASE CHARACTERISTICS: Diagnosis of primary malignant glioblastoma multiforme (i.e., grade IV anaplastic astrocytoma) Primary treatment (surgery, radiation, and/or chemotherapy) has been completed Candidate for surgery and willing to undergo craniotomy No progressive or recurrent disease No residual disease that requires reoperation, additional gamma therapy, or other modality PATIENT CHARACTERISTICS: ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100% (i.e., if symptomatic, bedridden < half of a waking day) Life expectancy ≥ 2 months Not pregnant Negative pregnancy test U.S. residents only No hematopoietic, hepatic, renal, cardiovascular, or pulmonary laboratory values or other medical circumstances that would preclude surgery or aldesleukin therapy No serious concurrent medical or psychiatric illness that would preclude informed consent or study treatment PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 4 weeks since prior anticancer therapy and recovered Prior stereotactic or gamma knife radiosurgery allowed